SignalGeopolitics
Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick
White House withdrawal of Trump's FDA pick lifts Capricor and Regenxbio shares.
Context
What happened: The White House withdrew its nomination for FDA commissioner. Capricor and Regenxbio were among the stocks that gained after the news.
Why it matters: The article says uncertainty around agency leadership complicates assumptions about review timelines and consistency, and that the deeper leadership problem remains unresolved with an acting commissioner expected to lead.
Key numbers: RP1 received accelerated approval; Capricor's Deramiocel application is under review; Regenxbio plans to resubmit RGX-121.
Coverage: 3 outlets in 24h
What changed
The White House withdrew its nomination for FDA commissioner. Capricor and Regenxbio were among the stocks that gained after the news.
Why it matters
The article says uncertainty around agency leadership complicates assumptions about review timelines and consistency, and that the deeper leadership problem remains unresolved with an acting commissioner expected to lead.
Key numbers: RP1 received accelerated approval; Capricor's Deramiocel application is under review; Regenxbio plans to resubmit RGX-121.